Douglas Neeld, MD
Allergy & Immunology · Fort Wayne, INNPI 1780669374
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,600 of the $76,544 with a category attached, or 85.7%. GSK accounts for 90.1% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2021 at $23,950 and has fallen 95.5% since, to $1,084 in 2025.
Across 411 payments — averaging $186.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$69K
- AstraZeneca$2K
- CSL Behring$1K
- Sanofi$857
- Takeda Pharmaceuticals U.S.A., Inc.$816
- Regeneron Healthcare Solutions, Inc.$358
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$65,60086%
- Travel & lodging$5501%
- Food & beverage$10,25713%
- Education$1370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 112 | $68,944 |
| AstraZeneca | 62 | $1,770 |
| CSL Behring | 50 | $1,253 |
| Sanofi | 26 | $857 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $816 |
| Regeneron Healthcare Solutions, Inc. | 13 | $358 |
| Amgen | 7 | $251 |
| Biocryst US Sales Co., LLC | 12 | $244 |
| Pharming Healthcare, Inc. | 11 | $226 |
| Genentech USA, Inc. | 7 | $224 |
| Novartis | 9 | $184 |
| Boehringer Ingelheim | 10 | $183 |
| Octapharma USA, Inc. | 3 | $178 |
| Kaleo, Inc. | 11 | $152 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $144 |
| Shire North American Group Inc | 2 | $113 |
| Grifols USA, LLC | 6 | $104 |
| Bio Products Laboratory USA, Inc. | 1 | $75 |
| Optinose US, Inc. | 4 | $65 |
| Pfizer | 4 | $63 |
| Aimmune Therapeutics, Inc. | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $53 |
| Hospira, Inc. | 2 | $34 |
| Alk-abello, Inc | 2 | $32 |
| Merck | 2 | $27 |
| Blueprint Medicines Corporation | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| AbbVie | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,544 in reported general payments places this provider in the 85th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BerinertC1 Esterase Inhibitor | 13 | $798,440 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 20 | $168,877 |
| Fasenra PenBenralizumab | 27 | $156,633 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $149,353 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 36 | $147,503 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 133 | $117,835 |
| TezspireTezepelumab-Ekko | 18 | $104,263 |
| Dupixent PenDupilumab | 25 | $92,804 |
| Breo ElliptaFluticasone/Vilanterol | 71 | $37,293 |
| Spiriva RespimatTiotropium Bromide | 64 | $36,923 |
| Advair HfaFluticasone Propion/Salmeterol | 69 | $26,283 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $17,372 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 99 | $10,811 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $10,439 |
| Arnuity ElliptaFluticasone Furoate | 43 | $10,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringBerinert, Hizentra | $1,253 | $947,79339 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $68,944 | $173,656267 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $816 | $168,87720 claims |
| Grifols USA, LLCGamunex-C | $104 | $147,50336 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,770 | $132,07477 claims |
| Boehringer IngelheimSpiriva Respimat | $183 | $36,92364 claims |
| MerckDulera | $27 | $5,16911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in Fort Wayne
- William SmitsFort Wayne$203K
- Diana Munoz-MendozaFort Wayne$8K
- Mohan MenonFort Wayne$6K
- Vanessa Cavero ChavezFort Wayne$4K
- Julia MontejoFort Wayne$64
- Nabeel FarooquiFishers$1.2M
- David PattersonNoblesville$252K
- Steven WiseIndianapolis$137K
- Majed KoleilatEvansville$122K
- Pinkus GoldbergIndianapolis$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.